Clinical Context Obesity affects over 650 million adults worldwide and is associated with numerous comorbidities including type 2 diabetes, cardiovascular…
Browsing: GLP-1 Receptor Agonists
Summary: In adults with overweight/obesity (BMI ≥27) and established atherosclerotic CVD, without diabetes, semaglutide 2.4 mg once weekly for median…
Summary: In adults with type 2 diabetes and chronic kidney disease on stable ACE inhibitor or ARB therapy, semaglutide 1.0…
Summary: In adults with type 2 diabetes (n=1,879) from SURPASS-2 Phase 3 trial, once-weekly tirzepatide (5, 10, or 15 mg)…
Summary: In adults from pooled SURPASS-1, -2, -3 trials (n=3,792), stratified by early-onset T2D (diagnosed <40 years) vs later-onset (≥40…
Summary: In 1,145 adults with obesity-related HFpEF (BMI ≥30, LVEF ≥45%, NYHA II-IV) pooled from STEP-HFpEF and STEP-HFpEF DM trials,…
Summary: In 616 adults with HFpEF (EF ≥45%), obesity (BMI ≥30), and type 2 diabetes, semaglutide 2.4 mg subcutaneous weekly…
A phase 1 clamp trial shows tirzepatide improves beta-cell function and insulin sensitivity more than semaglutide, explaining its glucose-lowering. PICO summary and commentary.
Summary: In 178 adults with T2D (HbA1c 7.0-10.5%) on stable metformin, once-weekly semaglutide (0.25-1.0 mg) for 52 weeks produced numerically…
Summary: In 1,748 adults with T2D (HbA1c 7.5-10.0%) inadequately controlled on basal insulin glargine and metformin, once-weekly semaglutide 1.0 mg…